23andMe Investor Presentation Deck

NEED: Our FXG Efforts Leverage Pleiotropy to Identify Targets in Defined Areas of Medical Need in Asthma 23andMe genetics 23andMe Asthma & COPD GWAS Eczema GWAS Bulk and single-cell RNA-seq In vitro functional genomics Gene Editing 32 days NHBE cells ALI culture Arrayed Library Disease-relevant readouts Barrier function Cell composition & mucin production Log10FU Negative Copyright © 2024 23andMe, Inc. CD63 STATE Positive STA FOX NO MUCS Validated targets with pharmacologically meaningful effects in disease relevant assays hom 23and Me 15

View entire presentation